In a March 11, 2013 ceremony in the Gordon Hall of Medicine at Harvard Medical School, Nancy Tarbell, HMS dean for academic and clinical affairs, acknowledged Paul Richardson of Dana-Farber Cancer Institute as the first incumbent of the R.J. Corman Professorship in Medicine.
Citing Richardson’s clinical and laboratory contributions to the treatment of multiple myeloma, Tarbell recognized him as “an outstanding member of our faculty, a dedicated researcher, an exceptional clinician and a very deserving inaugural incumbent for this great honor.”
In particular, Richardson was recognized for his pioneering use of combination therapies—most notably lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone, together known as RVD—to treat multiple myeloma.
The recipient of numerous awards honoring his excellence in both research and clinical care, Richardson shared the Warren Alpert Foundation Prize in 2012 for his contributions to the development of bortezomib as a front-line therapy for multiple myeloma.
The professorship was made possible through the generosity of Richard Corman, a tireless advocate for cancer research and a passionate, long-standing supporter of Dana-Farber.
Speakers at the professorship celebration included Edward Benz, Jr., president and CEO of Dana-Farber and the HMS Richard and Susan Smith Professor of Medicine at Dana-Farber; James Griffin, HMS professor of medicine and chair of medical oncology at Dana-Farber; George Canellos, the HMS William Rosenberg Professor of Medicine at Dana-Farber; Robert Soiffer, HMS professor of medicine, chief of hematologic malignancies and co-chief of the Stem Cell/Bone Marrow Transplantation Program at Dana-Farber; and Kenneth Anderson, the HMS Kraft Family Professor of Medicine at Dana-Farber and director of the Jerome Lipper Multiple Myeloma Center and the LeBow Institute for Myeloma Therapeutics at Dana-Farber.
